Physician profile
Anja Wagner
NPI 1699909432
$2,311.63
in general payments reported to CMS, 2019-2025
20 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $16.03 · 2021: $73.88 · 2022: $45.66 · 2023: $260 · 2024: $99.11 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $381.53 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $211.73 | 2019 | |
| Pfizer INC. | $189.87 | 2019-2021 | |
| Abbott Laboratories | $171.54 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Triclip |
| Amgen INC. | $160.80 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $158.29 | 2019-2020 | |
| Heartflow, INC. | $147.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $134.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.33 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $128.94 | 2021-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $126.30 | 2019 | |
| Intuitive Surgical, INC. | $97.91 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $77.45 | 2019 | |
| Amarin Pharma, INC. | $36.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $33.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.57 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.91 | 2019 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Gilead Sciences, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anja Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.